ArriVent BioPharma, Inc. AVBP Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.1M+24.5% | $45.54M-38.7% | $112.67M-60.2% | $112.77M— | $49.87M— | ||
| $264.28M— | $267.28M— | $187.59M— | —— | —— | ||
| $77.81M+109% | $65.2M+73.5% | $53.24M+36.3% | $41.83M+53.1% | $37.21M+221% | ||
| $348.7M+87.7% | $332.9M+46.7% | $321.22M+9.9% | $250.15M— | $185.79M— | ||
| $370K+208% | $13K-91.6% | $49K-73.8% | $85K— | $120K— | ||
| $156K-11.4% | $190K+50.8% | $180K+42.9% | $479K— | $176K— | ||
| $349.3M+62.1% | $333.17M+21.2% | $326.56M+11.6% | $269.51M— | $215.5M— | ||
| $8.73M+100.0% | $5.93M+56.9% | $5.93M+27.7% | $4.06M— | $4.36M— | ||
| $16.17M+91.3% | $20M+50.0% | $15.57M+50.3% | $15.48M— | $8.45M— | ||
| $99K-28.3% | $14K-91.4% | $56K-64.3% | $98K— | $138K— | ||
| $25M+93.0% | $25.95M+50.2% | $21.56M+42.2% | $19.64M— | $12.95M— | ||
| —— | —— | —— | —— | —— | ||
| $25.32M+95.4% | $25.95M+50.1% | $21.56M+41.7% | $19.64M— | $12.95M— | ||
| $5K+25.0% | $4K+33.3% | $4K— | $4K— | $4K— | ||
| $772.21M+52.8% | $711.85M+43.5% | $673.88M+36.1% | $584M— | $505.28M— | ||
| -$447.96M-48.0% | -$404.64M-69.8% | -$369.1M-69.5% | -$334.12M— | -$302.72M— | ||
| -$270K— | $14K— | $206K— | —— | —— | ||
| $323.98M+60.0% | $307.22M+19.2% | $305M+9.9% | $249.87M-15.8% | $202.54M-36.3% | ||
| $349.3M+62.1% | $333.17M+21.2% | $326.56M+11.6% | $269.51M— | $215.5M— | ||
| $156K-11.4% | $190K+50.8% | $180K+42.9% | $479K— | $176K— | ||
| $370K+208% | $13K-91.6% | $49K-73.8% | $85K— | $120K— | ||
| —— | —— | —— | —— | —— | ||
| $370K+208% | $13K-91.6% | $49K-73.8% | $85K— | $120K— | ||
| $156K-11.4% | $190K+50.8% | $180K+42.9% | $479K— | $176K— | ||
| $264.28M— | $267.28M— | $187.59M— | —— | —— | ||
| $370K+208% | $13K-91.6% | $49K-73.8% | $85K— | $120K— | ||
| $156K-11.4% | $190K+50.8% | $180K+42.9% | $479K— | $176K— | ||
| $16.17M+91.3% | $20M+50.0% | $15.57M+50.3% | $15.48M— | $8.45M— | ||
| $16.17M+91.3% | $20M+50.0% | $15.57M+50.3% | $15.48M— | $8.45M— | ||
| $419K+204% | $14K-92.0% | $56K-73.7% | $98K— | $138K— | ||
| $5K+25.0% | $4K+33.3% | $4K— | $4K— | $4K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ArriVent BioPharma, Inc.'s total assets?
- ArriVent BioPharma, Inc. (AVBP) holds $349.3M in total assets, up 62.1% year over year.
- How much debt does ArriVent BioPharma, Inc. have?
- ArriVent BioPharma, Inc. carries $419.0K in total debt against $324.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does ArriVent BioPharma, Inc. have?
- ArriVent BioPharma, Inc. holds $62.1M in cash and equivalents.
- Can ArriVent BioPharma, Inc. cover its short-term obligations?
- Its current ratio is 13.95 — current assets exceed current liabilities.
- Where does ArriVent BioPharma, Inc.'s balance sheet data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.